The US Food and Drug Administration (FDA) has granted 510(k) clearance for Varian’s IntelliBlate microwave ablation system, designed for soft tissue ablation.

The system is engineered to offer clinicians increased predictability, precision, and control during ablation procedures. It creates large, controlled spherical ablation zones, ensuring predictable treatment outcomes.

The system's flexibility is highlighted by its dual probe capability, with each probe featuring either linked or independent controls to cater to individual patient needs.

Further enhancing the system's precision is the Ximitry probe, which introduces advanced features such as LED indicators and laser disk alignment.

The IntelliBlate system's compact and versatile design, coupled with an intuitive interface, provides a flexible solution that simplifies the adoption of microwave ablation.

Looking ahead, Varian, a Siemens Healthineers company, plans to integrate intelligent therapeutic technologies and image-guided innovations into a unified platform.

The integration aims to offer clinicians enhanced predictability in probe placement, treatment delivery, and procedural confirmation.

Varian Interventional Solutions vice-president and chief medical officer Dr David Hahn said: “IntelliBlate combines the features our customers say are most important for an efficient, integrated solution to seek improved levels of performance in microwave ablation.

“This innovative system brings new versatility in treatment options, fueling clinician-driven innovation to tackle a wide variety of cases. Real-time monitoring and treatment information at the tissue level aim to further empower care teams with the confidence to deliver highly personalised care to patients.”

In partnership with Siemens Healthineers, Varian continues to invest in the development of integrated microwave ablation technologies that combine therapy and image-guided solutions.